Verified Nov 2026
Batteries & E-Mobility
·
Concord, California
·
Since 1992
Cerus Corporation, founded in 1992 and headquartered in Concord, California, is a publicly traded company (ticker CERS) with 200-500 employees and revenue in the $206.1M band. It develops pathogen reduction technology for blood safety, with its core INTERCEPT Blood System used to inactivate pathogens in platelets and plasma. Its customers include blood centers, hospitals, and national blood services, and its industries are listed as healthcare, medical devices, and biotechnology. In April 2026, it announced a new four-year supply agreement with a French blood establishment for the INTERCEPT Blood System.
Cerus at a glance
Revenue
206.1M
Employees
200-500
Founded
1992
Headquarters
Concord, California
Ownership
Publicly traded (NASDAQ: CERS)
Import activity
416
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
416
Named foreign suppliers
13
Top origins
Netherlands · France · Belgium · Germany
Shared foreign counterparties do not establish that these companies buy from Cerus.
What this tells a buyer
Cerus announced a new four-year supply agreement with a French blood establishment for the INTERCEPT Blood System on April 27, 2026.
Its core product is the INTERCEPT Blood System, which uses photochemical pathogen inactivation for platelets and plasma, supported by the INTERCEPT Illuminator.
Cerus is publicly listed with 200-500 employees and reported revenue in the $206.1M band, and it appointed Vivek Jayaraman as President and Chief Executive Officer in March 2026.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Cerus Corporation, founded in 1992 and headquartered in Concord, California, is a publicly traded company (ticker CERS) with 200-500 employees and revenue in the $206.1M band. It develops pathogen reduction technology for blood safety, with its core INTERCEPT Blood System used to inactivate pathogens in platelets and plasma. Its customers include blood centers, hospitals, and national blood services, and its industries are listed as healthcare, medical devices, and biotechnology. In April 2026, it announced a new four-year supply agreement with a French blood establishment for the INTERCEPT Blood System.
At a glance
Attribute | Detail |
|---|---|
Founded | 1992 |
Headquarters | Concord, California |
Employees | 200-500 |
Revenue | 206.1M |
Ownership | Publicly traded (NASDAQ: CERS) |
Primary capability | Batteries & E-Mobility |
What Cerus makes
Its core product is the INTERCEPT Blood System, which uses photochemical pathogen inactivation for platelets and plasma, supported by the INTERCEPT Illuminator.
Products and capabilities described on the company's own site include LED (source: cerus.com).
Trade and customs footprint
Cerus announced a new four-year supply agreement with a French blood establishment for the INTERCEPT Blood System on April 27, 2026. US customs bill-of-lading records list 416 inbound shipments across 13 foreign suppliers, with top origins including Netherlands · France · Belgium · Germany.
Latest developments
2026-11-02 — Cerus Corporation Announces Third Quarter 2026 Financial Results (businesswire.com)
2026-07-30 — Cerus Corporation - Cerus Corporation Announces Second Quarter 2026 Financial Results (cerus.com)
2026-06-08 — Cerus Corporation Closes New Debt Facility of Up to $110 Million | Morningstar (morningstar.com)
2026-04-27 — Cerus Corporation - Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System (cerus.com)
2026-03-16 — Cerus Corporation - Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer (cerus.com)
2025-12-10 — Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America (yahoo.com)
Company details
Cerus is publicly listed with 200-500 employees and reported revenue in the $206.1M band, and it appointed Vivek Jayaraman as President and Chief Executive Officer in March 2026. Cerus was founded in 1992, has an estimated 200-500 employees, and is headquartered in Concord, California.
Frequently asked questions
What does Cerus make?
Cerus Corporation, founded in 1992 and headquartered in Concord, California, is a publicly traded company (ticker CERS) with 200-500 employees and revenue in the $206.1M band. It develops pathogen reduction technology for blood safety, with its core INTERCEPT Blood System used to inactivate pathogens in platelets and plasma. Its customers include blood centers, hospitals, and national blood services, and its industries are listed as healthcare, medical devices, and biotechnology. In April 2026, it announced a new four-year supply agreement with a French blood establishment for the INTERCEPT Blood System.
Where is Cerus headquartered?
Cerus is headquartered in Concord, California (1220 Concord Ave, Concord, California, 94520-4906).
When was Cerus founded?
Cerus was founded in 1992.
How big is Cerus?
Cerus has an estimated 200-500 employees, with revenue in the 206.1M range.
Is Cerus publicly traded?
Publicly traded (NASDAQ: CERS). Public financial figures are drawn from its filings.
Does Cerus import from overseas suppliers?
US customs bill-of-lading records show 416 inbound shipments for Cerus, with top origins including Netherlands · France · Belgium · Germany.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.